Precision pathology as applied to breast core needle biopsy evaluation: implications for management.
Review
Overview
abstract
With the shift to de-escalation of therapy for some breast cancers and fewer surgical excisions for high-risk lesions identified on breast imaging studies at one end of the spectrum, and the greater use of neoadjuvant systemic therapy at the other end, pathologists are ever more critical in guiding management decisions for women with breast disease following core needle biopsy. One important consequence of this shift in management paradigms is the elimination of the opportunity for a "second-look" with the excision specimen to confirm or refine the diagnosis rendered on core needle biopsy. Thus, not only is there the imperative for accuracy and precision of core needle biopsy diagnoses, increasingly it is the only opportunity for that diagnosis.